124 related articles for article (PubMed ID: 180741)
21. Pituitary-adrenal responses to corticotropin-releasing hormone in different degrees of adrenal 21-hydroxylase deficiency.
Moreira AC; Elias LL
J Clin Endocrinol Metab; 1992 Jan; 74(1):198-203. PubMed ID: 1309366
[TBL] [Abstract][Full Text] [Related]
22. Plasma 17 alpha-hydroxyprogesterone and aldosterone concentrations in infants and children with congenital adrenal hyperplasia--the role of salt-losing hormones in salt wasting.
Holcombe JH; Keenan BS; Clayton GW
J Pediatr; 1981 Apr; 98(4):573-5. PubMed ID: 7205484
[No Abstract] [Full Text] [Related]
23. Increased plasma 21-deoxycorticosterone (21-DB) levels in late-onset adrenal 21-hydroxylase deficiency suggest a mild defect of the mineralocorticoid pathway.
Fiet J; Gueux B; Raux-DeMay MC; Kuttenn F; Vexiau P; Brerault JL; Couillin P; Galons H; Villette JM; Julien R
J Clin Endocrinol Metab; 1989 Mar; 68(3):542-7. PubMed ID: 2537337
[TBL] [Abstract][Full Text] [Related]
24. The effect of ACTH on the blood clearance rate of aldosterone, cortisol, 17 alpha-hydroxyprogesterone and 17 alpha, 20 alpha-dihydroxy-4-pregnen-3-one in the sheep.
Soding P; Coghlan JP; Denton DA; Graham WF; Humphery TJ; Scoggins BA
J Steroid Biochem; 1983 Feb; 18(2):173-7. PubMed ID: 6302397
[TBL] [Abstract][Full Text] [Related]
25. Evidence for partial 21-hydroxylase deficiency among heterozygote carriers of congenital adrenal hyperplasia.
Lee PA; Gareis JF
J Clin Endocrinol Metab; 1975 Aug; 41(2):415-8. PubMed ID: 169282
[TBL] [Abstract][Full Text] [Related]
26. A contribution to the classification of cases of non-classic 21-hydroxylase-deficient congenital adrenal hyperplasia.
Phocas I; Chryssikopoulos A; Sarandakou A; Rizos D; Trakakis E
Gynecol Endocrinol; 1995 Sep; 9(3):229-38. PubMed ID: 8540293
[TBL] [Abstract][Full Text] [Related]
27. Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia.
Frisch H; Parth K; Schober E; Swoboda W
Arch Dis Child; 1981 Mar; 56(3):208-13. PubMed ID: 7212759
[TBL] [Abstract][Full Text] [Related]
28. Unusual heterozygotes of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Zachmann M; Prader A
Acta Endocrinol (Copenh); 1978 Mar; 87(3):557-65. PubMed ID: 580145
[TBL] [Abstract][Full Text] [Related]
29. Partial deficiency of adrenal 11-hydroxylase. A possible cause of primary hypertension.
de Simone G; Tommaselli AP; Rossi R; Valentino R; Lauria R; Scopacasa F; Lombardi G
Hypertension; 1985; 7(2):204-10. PubMed ID: 2984117
[TBL] [Abstract][Full Text] [Related]
30. The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia.
Gutai JP; Kowarski AA; Migeon CJ
J Pediatr; 1977 Jun; 90(6):924-9. PubMed ID: 192874
[TBL] [Abstract][Full Text] [Related]
31. On the prenatal diagnosis of congenital adrenal hyperplasia (CAH) by measurement of amniotic fluid 17-alpha-hydroxyprogesterone, aldosterone and cortisol.
Grankvist K; Bäckström BT; Gustavsson G; Holmgren G
Acta Obstet Gynecol Scand; 1989; 68(1):71-4. PubMed ID: 2801032
[TBL] [Abstract][Full Text] [Related]
32. High aldosterone and cortisol levels in salt wasting congenital adrenal hyperplasia: a clinical conundrum.
Boddu SK; Madhavan S
J Pediatr Endocrinol Metab; 2017 Nov; 30(12):1327-1331. PubMed ID: 29127765
[TBL] [Abstract][Full Text] [Related]
33. Pregnenolone, 17-OH-pregnenolone, and testosterone in plasma of patients with congenital adrenal hyperplasia.
McKenna TJ; Jennings AS; Liddle GW; Burr IM
J Clin Endocrinol Metab; 1976 May; 42(5):918-25. PubMed ID: 178685
[TBL] [Abstract][Full Text] [Related]
34. The hypothalamic-pituitary-adrenal axis in partial (late-onset) 21-hydroxylase deficiency.
Feuillan P; Pang S; Schürmeyer T; Avgerinos PC; Chrousos GP
J Clin Endocrinol Metab; 1988 Jul; 67(1):154-60. PubMed ID: 2837498
[TBL] [Abstract][Full Text] [Related]
35. Plasma renin activity and aldosterone concentration in normal subjects and patients with salt-losing type of congenital adrenal hyperplasia during infancy.
Koshimizu T
Clin Endocrinol (Oxf); 1979 May; 10(5):515-22. PubMed ID: 225066
[No Abstract] [Full Text] [Related]
36. Effect of cortisol treatment on hormonal relationships in congenital adrenal hyperplasia.
Bacon GE; Spencer ML; Kelch RP
Clin Endocrinol (Oxf); 1977 Feb; 6(2):113-26. PubMed ID: 844219
[TBL] [Abstract][Full Text] [Related]
37. Impaired mineralocorticoid hormone responses to adrenocorticotropin stimulation: additional characterization of heterozygosity for the 21-hydroxylase deficiency type of congenital adrenal hyperplasia.
Pardini DP; Kater CE; Vieira JG; Biglieri EG
J Clin Endocrinol Metab; 1983 Nov; 57(5):1061-6. PubMed ID: 6311859
[TBL] [Abstract][Full Text] [Related]
38. 17-Hydroxyprogesterone in children, adolescents and adults.
Honour JW
Ann Clin Biochem; 2014 Jul; 51(Pt 4):424-40. PubMed ID: 24711560
[TBL] [Abstract][Full Text] [Related]
39. Continuing need for mineralocorticoid therapy in salt-losing congenital adrenal hyperplasia.
Hughes IA; Wilton A; Lole CA; Gray OP
Arch Dis Child; 1979 May; 54(5):350-5. PubMed ID: 475410
[TBL] [Abstract][Full Text] [Related]
40. The simultaneous assay of cortisol and 17alpha-hydroxyprogesterone in the plasma of patients with congenital adrenal hyperplasia.
Pham-Huu-Trung MT; Gourmelen M; Girard F
Acta Endocrinol (Copenh); 1973 Oct; 74(2):316-30. PubMed ID: 4355076
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
